49 completed, 32 unknown, 8 recruiting, 8 terminated. 47 Not applicable, 21 Phase 4, 13 Phase 3, 6 Phase 2, 2 Phase 1.
Follow Overactive Bladder Syndrome: new trials by email Literature Review of Overactive Bladder Syndrome trials Research Report on Overactive Bladder Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in Children Urgent PC - Overactive Bladder, Overactive Bladder Syndrome | Phase 4 | Not yet recruiting | Chi Dang Hornik | 50 | 2027-04-01 | 2026-06-17 |
| Efficacy and Safety of Peroneal Electric Transcutaneous Neuromodulation in the Real-world Clinical Practice Peroneal eTNM - Overactive Bladder Syndrome | Not yet recruiting | University Hospital Ostrava | 300 | 2026-09-01 | 2026-09-01 | |
| Real-world Experiences and Voices Exploring the Actual Lived Burden of OAB: A Mixed-methods Multi-country PROMs Study on OAB Patients' Quality of Life Overactive Bladder (OAB), Overactive Bladder Syndrome | Not yet recruiting | European Association of Urology Research Foundation | 2000 | 2026-07-01 | 2026-05-06 | |
| Moving Beyond p-Values: MCID for OAB-V8 8 and ICIQ-SF in Patients With OAB Behavioral therapy and transcutaneous posterior tibial nerve stimulation - Overactive Bladder Syndrome | Not applicable | Completed | Artvin Coruh University | 104 | 2026-01-01 | 2026-08-28 |
| Yoga for Treatment of Overactive Bladder in Pediatric Patients Yoga - Overactive Bladder, Overactive Bladder Syndrome | Not applicable | Terminated | Duke University | 1 | 2025-10-12 | 2026-08-20 |
| Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study Tadalafil 5 mg, Solifenacin 5mg - Overactive Bladder (OAB), Overactive Bladder Syndrome | Phase 4 | Recruiting | Mansoura University | 480 | 2025-09-01 | 2026-02-18 |
| Home-Based Transcutaneous Remotely Monitored Posterior Tibial Neuromodulation Efficacy of remotely monitored transcutaneous posterior tibial nerve neuromodulation via a test device at 12 week and 12 month, Efficacy of remotely monitored transcutaneous posterior tibial nerve neuromodulation via a placebo device at 12 week - Overactive Bladder Syndrome, Overactive Bladder (OAB) | Not applicable | Recruiting | Ege University | 50 | 2025-06-24 | 2025-07-23 |
| Prevalence And Risk Factors of Overactive Bladder Syndrome Among Egyptian Medical Students, and Their Impact On Health-Related Quality Of Life Questionnaire - Overactive Bladder Syndrome | Completed | Zagazig University | 1003 | 2025-05-15 | 2025-07-03 | |
| Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial Platelet-Rich Plasma, Intravesical Botulinum Toxin Injection - Overactive Bladder Syndrome, Urinary Urge Incontinence | Not applicable | Completed | Benha University | 49 | 2025-04-15 | 2026-11-05 |
| Oral Lactobacillus Supplementation as Treatment for Overactive Bladder Syndrome: A Randomised Controlled Trial OMNi BiOTiC® 41167, Placebo - Overactive Bladder Syndrome | Not applicable | Recruiting | Medical University of Vienna | 100 | 2025-04-01 | 2025-09-29 |
| Role of Combination Therapy in Women With Refractory Overactive Bladder Vibegron 75mg, Placebo - Overactive Bladder Syndrome | Not applicable | Withdrawn | University of Alabama at Birmingham | 2025-01-01 | 2026-02-12 | |
| Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections Lidocaine 2% without vessel constrictor - Overactive Bladder, Overactive Bladder Syndrome | Phase 4 | Not yet recruiting | University of Louisville | 36 | 2024-12-01 | 2024-11-19 |
| Improving Overactive Bladder Treatment Access and Adherence Patient Engagement Tool - Overactive Bladder Syndrome, Urinary Incontinence | Not applicable | Recruiting | Stanford University | 30 | 2024-11-01 | 2026-07-21 |
| Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Syndrome and Associated Gait Changes in Post-menopausal Women Transcutaneous tibial nerve stimulation - Overactive Bladder Syndrome, Urinary Incontinence, Urge | Not applicable | Unknown | Louisiana State University Health Sciences Center Shreveport | 60 | 2024-10-01 | 2024-09-27 |
| Overactive Bladder Syndrome and Hypopressive Exercise Online hypopressive exercise training program - Overactive Bladder Syndrome | Not applicable | Enrolling by invitation | Pamukkale University | 112 | 2024-08-30 | 2025-01-17 |
| RCT on Multimodal Self-treatment for Women With Incontinence Using a Digital Health Application Kranus Mictera - Urinary Incontinence,Stress, Urinary Incontinence, Urge | Not applicable | Completed | Kranus Health GmbH | 194 | 2024-04-30 | 2026-04-28 |
| Cyclic Versus Continuous Sacral Neuromodulation for LUTS Cyclic SNM, Continuous SNM - Overactive Bladder Syndrome | Not applicable | Completed | University Hospitals Cleveland Medical Center | 50 | 2024-04-15 | 2026-07-24 |
| Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women vaginal 17 beta-estradiol, Placebo, Behavioral modifications - Lower Urinary Tract Symptoms, Female Genitourinary Disease | Phase 4 | Completed | Mahidol University | 86 | 2024-04-08 | 2025-04-20 |
| Migraine Medication Effects on Urinary Symptoms Ubrogepant, Rimegepant, Atogepant - Overactive Bladder, Bladder Pain Syndrome | Enrolling by invitation | The Cleveland Clinic | 200 | 2024-04-05 | 2026-10-19 | |
| Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome MitoQ (mitoquinol mesylate), Placebo - Lower Urinary Tract Symptoms, Overactive Bladder Syndrome | Phase 2 | Terminated | Iman Al-Naggar, PhD | 20 | 2024-04-03 | 2026-05-01 |
Showing 20 of 110. Sign in to see all of them.
Urinary Bladder, Overactive (48) · Urinary Incontinence, Urge (19) · Urinary Incontinence (10) · Lower Urinary Tract Symptoms (6) · Urologic Diseases (4) · Multiple Sclerosis (3) · Nocturia (3) · Urinary Incontinence, Stress (3) · Cystitis, Interstitial (2) · Urinary Bladder Diseases (2) · Urinary Bladder, Neurogenic (2) · Urinary Tract Infections (2) · Anticholinergic Syndrome (1) · Chronic Pain (1) · Coronary Artery Disease (1)
Pathological Conditions, Signs and Symptoms (62) · Signs and Symptoms (62) · Urogenital Diseases (62) · Female Urogenital Diseases and Pregnancy Complications (61) · Male Urogenital Diseases (61) · Female Urogenital Diseases (60) · Urological Manifestations (60) · Urologic Diseases (57) · Lower Urinary Tract Symptoms (54) · Urinary Bladder Diseases (49) · Urination Disorders (29) · Urinary Incontinence (17) · Nervous System Diseases (9) · Autoimmune Diseases (4) · Immune System Diseases (4)
mirabegron (12) · Solifenacin Succinate (11) · Botulinum Toxins, Type A (8) · Tolterodine Tartrate (3) · darifenacin (3) · Behavior Therapy (2) · Estradiol (2) · Lidocaine (2) · incobotulinumtoxinA (2) · oxybutynin (2) · 4,4',5'-trimethylazapsoralen (1) · AIEOP acute lymphoblastic leukemia protocol (1) · Acupuncture Therapy (1) · Anti-Bacterial Agents (1) · Antibiotic Prophylaxis (1)
Far Eastern Memorial Hospital (6) · Maastricht University Medical Center (5) · Buddhist Tzu Chi General Hospital (4) · Pfizer (4) · Ege University (3) · Mansoura University (3) · National Taiwan University Hospital (3) · University Hospital, Ghent (3) · Cairo University (2) · Corewell Health East (2) · Novartis (2) · Radboud University Medical Center (2) · The Cleveland Clinic (2) · University of Sao Paulo General Hospital (2) · University of Zurich (2)
United States (31) · Taiwan (17) · Turkey (Türkiye) (13) · Netherlands (9) · Egypt (5) · Belgium (4) · Brazil (4) · Germany (4) · Colombia (2) · Italy (2) · Spain (2) · Switzerland (2) · Thailand (2) · United Kingdom (2) · Argentina (1)
Axel Steinert (2) · Hann-Chorng Kuo, M.D. (2) · Ahana Gaurav (1) · Ahmed A Shokeir, professor of urology (1) · Ahmed Shoma, MD (1) · Ahmet Ozgur OY Yeniel (1) · Amy Krambeck, MD (1) · Anna C Kirby, MD (1) · Anna S Trikhacheva, MD (1) · Antonella Giannantoni, M.D. (1) · Axel Haferkamp, PhD (1) · Basri Cakiroglu (1)
PMID 37160401, PMID 11857671, PMID 10027879, PMID 10188996, PMID 10797303, PMID 10925088, PMID 11176403, PMID 11176525, PMID 11412210, PMID 12007519, PMID 12579626, PMID 12579627, PMID 12811491, PMID 12894267, PMID 14693111, PMID 14973214, PMID 15449637, PMID 16406907, PMID 16753445, PMID 16813910, PMID 17010004, PMID 17049716, PMID 17385940, PMID 17574730, PMID 18311486, PMID 18423678, PMID 18565239, PMID 18663723, PMID 19089891, PMID 19220267, PMID 19254402, PMID 19281469, PMID 1939656, PMID 19625056, PMID 19683731, PMID 19816919, PMID 19889062, PMID 19941278, PMID 20121659, PMID 20132203, PMID 20171668, PMID 20567947, PMID 20590544, PMID 20723260, PMID 21092997, PMID 21130559, PMID 21371240, PMID 21501328, PMID 22182409, PMID 22258963
P30AG067988 (1)